Abstract
Background
Cytoreductive therapy for metastatic carcinoid provides symptomatic relief and improvement in overall survival. We evaluated whether CgA and 5HIAA could predict symptomatic relief and control of disease progression after cytoreductive surgery.
Methods
We retrospectively reviewed 70 patients who underwent cytoreductive surgery for neuroendocrine hepatic metastases between 1996 and 2005. Twenty-two patients had pre and post-operative CgA and/or 5HIAA levels measured. Reduction of biomarkers following cytoreduction was correlated with patient symptoms and progression of disease following surgery.
Results
Our study consisted of 14 males and 8 females with a mean age of 55 (±12 years). Median follow-up was 18 months (range 5-64 months). Six patients (26.1%) had complete (R0) cytoreduction, while 4 (17.4%) and 13 (56.5%) had microscopic (R1) and gross (R2) disease remaining. All patients reported improvements in their symptoms, with 12 (54.5%) reporting complete resolution (CR) and 10 (45.5%) reporting partial resolution (PR). Reduction of CgA of ≥ 80% was highly predictive of complete resolution of symptoms (P = 0.007) and stabilization of disease (P = 0.034). Reduction of 5HIAA levels of ≥ 80% (or normalization) was predictive of symptomatic relief, but not progression of disease (P = 0.026 and P = 0.725). Five of six patients who had R0 resections had CR and were free of disease at last follow-up (median 24.5 months, range: 11–48, P = 0.002).
Conclusions
We conclude that ≥ 80% reduction in CgA level following cytoreductive surgery for carcinoid tumors is predictive of subsequent symptom relief and disease control. Substantial reduction in CgA is associated with improved patient outcomes, even after incomplete cytoreduction.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Capella C, Heitz PU, Hofler H, et al. Revised classification of neuroendocrine tumours of the lung, pancreas and gut. Virchows Arch 1995; 425:547–560
Oberg K, Kvols L, Caplin M, et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 2004; 15:966–973
Oberndorfer. Karzinoide tumoren des dunndarms. Franf Zschr Pathol 1907; 1:426–430
Boudreaux JP, Putty B, Frey DJ, et al. Surgical treatment of advanced-stage carcinoid tumors: lessons learned. Ann Surg 2005; 241:839–845; discussion 845–836
Atwell TD, Charboneau JW, Que FG, et al. Treatment of neuroendocrine cancer metastatic to the liver: the role of ablative techniques. Cardiovasc Intervent Radiol 2005; 28:409–421
Sartori P, Mussi C, Angelini C, et al. Palliative management strategies of advanced gastrointestinal carcinoid neoplasms. Langenbecks Arch Surg 2005; 390:391–396
Akerstrom G, Hellman P, Hessman O, Osmak L. Management of midgut carcinoids. J Surg Oncol 2005; 89:161–169
Touzios JG, Kiely JM, Pitt SC, et al. Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg 2005; 241:776–783; discussion 783–775
Westberg G, Wangberg B, Ahlman H, et al. Prediction of prognosis by echocardiography in patients with midgut carcinoid syndrome. Br J Surg 2001; 88:865–872
Rorstad O. Prognostic indicators for carcinoid neuroendocrine tumors of the gastrointestinal tract. J Surg Oncol 2005; 89:151–160
Feldman JM. Carcinoid tumors and the carcinoid syndrome. Curr Probl Surg 1989; 26:835–885
Agranovich AL, Anderson GH, Manji M, et al. Carcinoid tumour of the gastrointestinal tract: prognostic factors and disease outcome. J Surg Oncol 1991; 47:45–52
Janson ET, Holmberg L, Stridsberg M, et al. Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol 1997; 8:685–690
Granberg D, Wilander E, Stridsberg M, et al. Clinical symptoms, hormone profiles, treatment, and prognosis in patients with gastric carcinoids. Gut 1998; 43:223–228
Taupenot L, Harper KL, O’Connor DT. The chromogranin-secretogranin family. N Engl J Med 2003; 348:1134–1149
Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205–216
O’Toole D, Ruszniewski P. Chemoembolization and other ablative therapies for liver metastases of gastrointestinal endocrine tumours. Best Pract Res Clin Gastroenterol 2005; 19:585–594
Roche A, Girish BV, de Baere T, et al. Trans-catheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumors. Eur Radiol 2003; 13:136–140
Osborne DA, Zervos EE, Strosberg J, et al. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. Ann Surg Oncol 2006; 13:572–581
Stridsberg M, Eriksson B, Oberg K, Janson ET. A comparison between three commercial kits for chromogranin A measurements. J Endocrinol 2003; 177:337–341
Oberg K. Biochemical diagnosis of neuroendocrine GEP tumor. Yale J Biol Med 1997; 70:501–508
Ardill JE, Erikkson B. The importance of the measurement of circulating markers in patients with neuroendocrine tumours of the pancreas and gut. Endocr Relat Cancer 2003; 10:459–462
Nikou GC, Lygidakis NJ, Toubanakis C, et al. Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin-A, somatostatin receptor scintigraphy and somatostatin analogues. Hepatogastroenterology 2005; 52:731–741
Kolby L, Bernhardt P, Sward C, et al. Chromogranin A as a determinant of midgut carcinoid tumour volume. Regul Pept 2004; 120:269–273
Kerstrom G, Hellman P, Hessman O. Midgut carcinoid tumours: surgical treatment and prognosis. Best Pract Res Clin Gastroenterol 2005; 19:717–728
Makridis C, Ekbom A, Bring J, et al. Survival and daily physical activity in patients treated for advanced midgut carcinoid tumors. Surgery 1997; 122:1075–1082
Hellman P, Lundstrom T, Ohrvall U, et al. Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastases. World J Surg 2002; 26:991–997
Ahlman H, Wangberg B, Jansson S, et al. Management of disseminated midgut carcinoid tumours. Digestion 1991; 49:78–96
Wangberg B, Westberg G, Tylen U, et al. Survival of patients with disseminated midgut carcinoid tumors after aggressive tumor reduction. World J Surg 1996; 20:892–899; discussion 899
Author information
Authors and Affiliations
Corresponding author
Additional information
This study was approved by the University of South Florida Institutional Review Board and is in compliance with all regulations regarding management of personal health information.
This manuscript is submitted to Annals of Surgical Oncology for review and has not been submitted elsewhere for publication.
Rights and permissions
About this article
Cite this article
Jensen, E.H., Kvols, L., McLoughlin, J.M. et al. Biomarkers Predict Outcomes Following Cytoreductive Surgery for Hepatic Metastases from Functional Carcinoid Tumors. Ann Surg Oncol 14, 780–785 (2007). https://doi.org/10.1245/s10434-006-9148-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-006-9148-z